273 related articles for article (PubMed ID: 38212842)
1. A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer.
Shao H; Zhao M; Guan AJ; Shao T; Zhou D; Yu G; Tang W
BMC Med; 2024 Jan; 22(1):13. PubMed ID: 38212842
[TBL] [Abstract][Full Text] [Related]
2. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis.
Leung JH; Leung HWC; Wang SY; Huang SS; Chan ALF
Expert Opin Drug Saf; 2021 Aug; 20(8):949-957. PubMed ID: 34047239
[TBL] [Abstract][Full Text] [Related]
5. First-line CDK4/6 inhibitor-based combinations for HR+/HER2- advanced breast cancer: A Bayesian network meta-analysis.
Guo X; Zhou Y; Zhang K; Lu W; Zhong X; Wu S; Shen L; Chen H; Chen Y
J Evid Based Med; 2024 Mar; 17(1):106-118. PubMed ID: 38102891
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
[TBL] [Abstract][Full Text] [Related]
8. Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis.
Wang T; Shen G; Li J; Huo X; Wang M; Liu Z; Zhao F; Ren D; Zhao J
Curr Cancer Drug Targets; 2023; 23(9):718-730. PubMed ID: 37026492
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
Liu Y; Wu J; Ji Z; Chen L; Zou J; Zheng J; Lin W; Cai J; Chen Y; Zheng D; Chen Y; Li Z
BMC Cancer; 2023 Aug; 23(1):816. PubMed ID: 37653504
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
12. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Borstnar S; Palacova M; Łacko A; Timcheva C; Gal-Yam EN; Papazisis K; Beniak J; Kudela P; Rubovszky G
Radiol Oncol; 2022 May; 56(2):238-247. PubMed ID: 35575587
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
15. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
16. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
Brandão M; Maurer C; Ziegelmann PK; Pondé NF; Ferreira A; Martel S; Piccart M; de Azambuja E; Debiasi M; Lambertini M
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847835
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
20. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
